Watson Pharmaceuticals buys Ascent Pharmahealth
As per the agreement, Watson acquired Ascent Pharmahealth for AU$375 million (approximately $393 million) in cash. Watson expects the deal to be immediately accretive to 2012 non-GAAP earnings.
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).